![]() However, there was uncertainty around key assumptions in the analyses, such as the inclusion of a process-related improvement in quality of life associated with using flash glucose monitoring. Evidence from three cost-utility analyses identified in the literature showed the potential for FLFGM to be cost-effective in cost per quality-adjusted life years (QALY) terms. However, this evidence is of lower certainty than the evidence derived from RCTs. Large-scale audits of real-world evidence suggest a reduction in paramedic callouts, hospital admissions, visits to diabetes/endocrine specialists and primary care visits following initiation of FLFGM over follow up times of 7.5 to 14 months. For other outcomes (glycosylated haemoglobin levels, quality of life, and device-related adverse events) there was no convincing evidence of a difference between FLFGM and SMBG. The evidence also suggests people who use FLFGM are able to check their glucose more frequently by scanning the device than those who use SMBG. Overall, the results suggest Freestyle Libre flash glucose monitoring (FLFGM) is beneficial in terms of improving time spent in target glucose range (and thus avoiding episodes or hypo- or hyperglycaemia), although it should be noted that not all trials found conclusive evidence of a difference between the two interventions. All of the studies used the Freestyle Libre device (either Freestyle Libre or Freestyle Libre 2) and it was noted that the functionality of these two device iterations in terms of blood glucose measurement and monitoring is not significantly different. Seven RCTs compared flash glucose monitoring to self-monitoring of blood glucose (SMBG) in people with type 1 or type 2 diabetes, the majority of whom were treated with insulin. FreeStyle ® Libre Flash Glucose Monitoring System.This rapid review used evidence from randomised controlled trials (RCTs), existing evidence reviews, and non-randomised trials if limited outcome data from RCTs was available. 2015 Report on Diabetes: Driving Change. reserves the right to amend in part, or in its entirety, its Special Authorization guidelines. Special Authorization for Managed FormulariesĬlaimSecure Inc. $49 (reader- Extended Health Care benefit) ![]() The FreeStyle® Libre reader coverage will be similar to glucometers through Extended Health Care. The Special Authorization process will optimize use of this new system by reserving it for blood glucose monitoring in diabetic patients treated with insulin. To ensure cost-effective use of the FreeStyle® Libre system, the FreeStyle® Libre sensor will be covered under the drug plan through Special Authorization for ClaimSecure’s groups subscribing to Managed Formularies and Specialty Drug Stop Loss Programs. Current usage by ClaimSecure’s members shows that insulin-treated members test their blood glucose levels 2-3 times more often compared to non-insulin treated members. ![]() In comparison, the cost of diabetic test strips is $80-90 for 14 days in patients testing 7 times per day. The FreeStyle® Libre sensor is priced at $89 and provides testing for a 14 day period. By eliminating the routine finger-pricking, the FreeStyle® Libre system provides ease of monitoring, improves patient compliance and diabetes management. The FreeStyle® Libre sensor is worn on the back of the upper arm and measures glucose levels when patients place the handheld reader over the sensor. It consists of a small sensor and portable reader that replaces the traditional test strips and glucometer. The FreeStyle® Libre system is the first in a novel category of glucose monitoring systems. This method can be painful, inconvenient and requires patients to manually track readings to share with their healthcare providers. This sample is applied to a diabetic test strip to obtain a glucose reading. ![]() The current standard of care requires patients to prick their finger and obtain a blood sample. This testing helps patients monitor blood glucose levels to prevent disease complications. ĭiabetes management guidelines recommend blood glucose level testing up to 8 times per day for patients treated with insulin. Diabetes poses a significant economic burden to the healthcare system, with drug costs of $1.8 billion in 2015 that are expected to rise by more than 40% over the next 10 years. This disease is characterized by uncontrolled blood glucose levels that lead to an increased risk of complications such as heart disease, kidney disease, and nerve damage. FREESTYLE (R) - LIBRE - a novel flash glucose monitoring system Drug Review: Volume 17, Issue 11 - Download PDFĭiabetes is a chronic disease that has become a leading cause of morbidity and mortality in Canada.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |